Regarding the mutations we found in our patients collective, targeted therapy has been used with success in adenocarcinoma of the lung with EGFR mutations, PIK3 inhibitors in stage four melanoma or MEK inhibitors in inoperable plexiform neurofibromas with NF1 mutations [38,39,40]. This evidence concerns the gene PIK3CG and lung adenocarcinoma.